A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Summary

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Major Depressive Disorder (MDD)
• Depression in Adults
• Depression - Major Depressive Disorder
• Depression Disorders
• Depression Disorder
• Depression

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 85 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Cybin IRL Limited

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites